JP2002514919A - 多価ライブラリーおよびポリクローナルライブラリー - Google Patents

多価ライブラリーおよびポリクローナルライブラリー

Info

Publication number
JP2002514919A
JP2002514919A JP54607598A JP54607598A JP2002514919A JP 2002514919 A JP2002514919 A JP 2002514919A JP 54607598 A JP54607598 A JP 54607598A JP 54607598 A JP54607598 A JP 54607598A JP 2002514919 A JP2002514919 A JP 2002514919A
Authority
JP
Japan
Prior art keywords
library
antibody
phage
polypeptide
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54607598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514919A5 (OSRAM
Inventor
グレイ，ジェフ
ブークラー，ジョー
バルカーズ，ガナース
Original Assignee
バイオサイト ダイアグノスティックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/835,159 external-priority patent/US6555310B1/en
Priority claimed from US08/832,985 external-priority patent/US6057098A/en
Application filed by バイオサイト ダイアグノスティックス，インコーポレイテッド filed Critical バイオサイト ダイアグノスティックス，インコーポレイテッド
Publication of JP2002514919A publication Critical patent/JP2002514919A/ja
Publication of JP2002514919A5 publication Critical patent/JP2002514919A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP54607598A 1997-04-04 1998-04-03 多価ライブラリーおよびポリクローナルライブラリー Ceased JP2002514919A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/835,159 1997-04-04
US08/835,159 US6555310B1 (en) 1997-04-04 1997-04-04 Polyclonal libraries
US08/832,985 1997-04-04
US08/832,985 US6057098A (en) 1997-04-04 1997-04-04 Polyvalent display libraries
PCT/US1998/006704 WO1998047343A2 (en) 1997-04-04 1998-04-03 Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages

Publications (2)

Publication Number Publication Date
JP2002514919A true JP2002514919A (ja) 2002-05-21
JP2002514919A5 JP2002514919A5 (OSRAM) 2005-11-24

Family

ID=27125574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54607598A Ceased JP2002514919A (ja) 1997-04-04 1998-04-03 多価ライブラリーおよびポリクローナルライブラリー

Country Status (5)

Country Link
US (3) US6420113B1 (OSRAM)
EP (1) EP0985033A4 (OSRAM)
JP (1) JP2002514919A (OSRAM)
AU (1) AU8755798A (OSRAM)
WO (1) WO1998047343A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511268A (ja) * 2009-11-18 2013-04-04 ピエール、ファーブル、メディカマン 新規なファージディスプレイベクター

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
US6420110B1 (en) * 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US8288322B2 (en) * 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2798625C (en) * 2000-04-17 2017-01-24 Dyax Corp. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
EP1184458A1 (en) * 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
PT1360288E (pt) 2000-12-18 2011-03-07 Dyax Corp Bibliotecas orientadas de pacotes genéticos
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
US20040018556A1 (en) * 2002-07-29 2004-01-29 Cantor Thomas L. Reagent and method for determination of a substance using an immunoaggregator
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
CN1602962A (zh) * 2004-08-04 2005-04-06 任兆钧 口蹄疫全病毒基因工程疫苗及其制备方法
WO2006017694A1 (en) * 2004-08-05 2006-02-16 Biosite Incorporated Compositions and methods for phage display of polypeptides
WO2006031583A2 (en) * 2004-09-09 2006-03-23 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
WO2007103290A2 (en) * 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
US7833724B2 (en) 2006-03-20 2010-11-16 Teva Women's Health, Inc. Methods for comparing the immunogenicity of products and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
AU2008212820B2 (en) 2007-02-09 2014-01-30 Northwestern University Particles for detecting intracellular targets
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
JP5669397B2 (ja) * 2007-03-01 2015-02-12 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 同族抗体をクローニングするための方法
US8709980B2 (en) * 2007-03-26 2014-04-29 Celexion, Llc Cell surface display, screening and production of proteins of interest
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0818674B1 (pt) * 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
US20100025981A1 (en) * 2008-08-01 2010-02-04 Lay Thierry System and method for characterizing a beverage
WO2010022738A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
DK2365803T3 (en) 2008-11-24 2018-01-22 Univ Northwestern POLYVALENT RNA NANOPARTICLE COMPOSITIONS
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
JP2013504602A (ja) * 2009-09-14 2013-02-07 ダイアックス コーポレーション 新しく設計したｈｃｃｄｒ３を含む遺伝子パッケージライブラリー
EP2478101A1 (en) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
JP5866119B2 (ja) 2009-10-30 2016-02-17 ノースウェスタン ユニバーシティ 鋳型ナノ複合体
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
AU2011292497B2 (en) 2010-08-17 2015-10-15 PRRIL Holding B.V. A novel method for diagnosing Q-fever using a cellular immunological test
EP2619584B1 (en) 2010-09-21 2016-10-12 Stichting Katholieke Universiteit Novel method for diagnosing lyme disease using a cellular immunological test
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
WO2013035345A2 (en) 2011-09-09 2013-03-14 Osaka University Dengue-virus serotype neutralizing antibodies
JP2014526517A (ja) 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ 血液脳関門を通過することができるナノ抱合体
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2014142646A1 (en) 2013-03-13 2014-09-18 Stichting Katholieke Universiteit Q-fever diagnostic
CN105308460A (zh) 2013-05-02 2016-02-03 天主教大学基金会 个性化药物
JP6403668B2 (ja) 2013-05-30 2018-10-10 国立大学法人千葉大学 抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9993404B2 (en) 2015-01-15 2018-06-12 The Procter & Gamble Company Translucent hair conditioning composition
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
CN113484119B (zh) * 2021-09-07 2021-11-16 中国空气动力研究与发展中心低速空气动力研究所 一种飞机结冰力学性能测试样本制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) * 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
AU662148B2 (en) * 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
US6492160B1 (en) * 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) * 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
PT744958E (pt) * 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5766905A (en) * 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
EP0972183A4 (en) * 1997-04-04 2006-12-06 Biosite Inc METHODS USING MAGNETIC PARTICLES FOR CONCENTRATING LIGANDS
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511268A (ja) * 2009-11-18 2013-04-04 ピエール、ファーブル、メディカマン 新規なファージディスプレイベクター

Also Published As

Publication number Publication date
WO1998047343A2 (en) 1998-10-29
US6420113B1 (en) 2002-07-16
US20030104477A1 (en) 2003-06-05
US20050158796A1 (en) 2005-07-21
EP0985033A2 (en) 2000-03-15
AU8755798A (en) 1998-11-13
WO1998047343A3 (en) 1998-12-10
EP0985033A4 (en) 2005-07-13
WO1998047343A9 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
US6420113B1 (en) Chimeric polyclonal antibodies
US6986986B1 (en) Polyvalent display libraries
US5580717A (en) Recombinant library screening methods
DE69123156T2 (de) VERFAHREN ZUR ERZEUGUNG FUNKTIONELLER, EINKETTIGER Fv ANTIKOERPER-FRAGMENTE AUF BAKTERIOPHAGEN-OBERFLÄCHEN
US8476040B2 (en) Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
JP3507073B2 (ja) 特異的結合対の成員の製造方法
AU696293B2 (en) Process for generating specific antibodies
Benhar et al. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA′ fusions on live bacteria
JP2003530543A (ja) 検出試薬としてのヒト抗体
JP2003527832A (ja) ヒト抗体
JP4570565B2 (ja) ペリプラズム発現によるコンビナトリアルタンパク質ライブラリーのスクリーニング
JPH06506836A (ja) ファージミドを使用するヘテロ二重体受容体ライブラリー
US6555310B1 (en) Polyclonal libraries
JPH06508511A (ja) 特異的な結合ペアーの構成員の製造方法
JP2004000238A (ja) 表面レセプター及び表面異種タンパク質を同時発現するファージミド
CN105247050B (zh) 用于文库构建、亲和力结合剂筛选和其表达的整合系统
US8969253B2 (en) Method for screening phage display libraries against each other
CN101052879B (zh) 抗体文库筛选的方法
US20070042399A1 (en) Biological materials and uses thereof
US20070111259A1 (en) Human antibodies
JP2008515419A (ja) 抗体ライブラリーをスクリーニングする方法
Harvey Anchored periplasmic expression (APEx): a versatile technology for the flow cytometric selection of high affinity antibodies from Escherichia coli expressed libraries
Stephenson et al. Cell-based panning as a means to isolate phage display Fabs specific for a bacterial surface protein
Smith The Regulation of Peptide Mimotope/Epitope Recognition by Monoclonal Antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090721